Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Chiara Manai"'
Autor:
Alessandra Raimondi, Vittorina Zagonel, Paolo Manca, Chiara Manai, Francesca Daniel, Salvatore Corallo, Michele Prisciandaro, Andrea Spallanzani, Virginia Quarà, Carmen Belli, Marta Vaiani, Maria Di Bartolomeo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Immune checkpoint inhibitors (ICIs) are the new standard of care in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Since tumor response dynamic parameters already shown a stron
Externí odkaz:
https://doaj.org/article/0c99b7dcadd04b1880b45908a67bc52d
Autor:
Anna La Salvia, Raffaella Carletti, Monica Verrico, Tiziana Feola, Giulia Puliani, Massimiliano Bassi, Franz Sesti, Angelina Pernazza, Rossella Mazzilli, Giuseppe Lamberti, Alessandra Siciliani, Massimiliano Mancini, Chiara Manai, Federico Venuta, Mohsen Ibrahim, Silverio Tomao, Giulia D’Amati, Cira Di Gioia, Elisa Giannetta, Federico Cappuzzo, Antongiulio Faggiano
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 19; Pages: 5958
Well-differentiated lung neuroendocrine tumours (Lu-NETs), classified as typical (TC) and atypical (AC) carcinoids, represent 30% of NETs. Angiogenesis plays an essential role in NET development and progression. A higher vascular network is a marker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a2e86c95921c18775415cc3ac5ac87
https://doi.org/10.3390/jcm11195958
https://doi.org/10.3390/jcm11195958
Autor:
Francesca Bergamo, Veronica Di Antonio, Letizia Procaccio, Matteo Fassan, Vittorina Zagonel, Chiara Manai, Fotios Loupakis, Sara Lonardi
Publikováno v:
Expert review of respiratory medicine. 13(7)
Introduction: Lung metastases occur in 10-20% of patients with colorectal cancer (CRC). Most of them are treated with palliative intent and have a poor prognosis. Pulmonary metastasectomy may be a curative option for carefully selected patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d4a6c7b8833e0304a0aa8bc518e225
https://pubmed.ncbi.nlm.nih.gov/31119959
https://pubmed.ncbi.nlm.nih.gov/31119959
Autor:
Chiara Manai, Silvia Marsoni, Salvatore Siena, Salvatore Corallo, Caterina Marchiò, Giovanni Cappello, Alessio Amatu, Anna Sapino, Elisabetta Fenocchio, Andrea Sartore-Bianchi, Valter Torri, Sara Lonardi, Federica Tosi, Alberto Bardelli, Francesco Rua, Benedetta Mussolin, Francesca Daniel, Angelo Vanzulli, Filippo Pietrantonio, Paolo Manca
Publikováno v:
Journal of Clinical Oncology. 39:3506-3506
3506 Background: Despite advances in molecular segmentation of metastatic colorectal cancer (mCRC), beyond RAS status therapeutic actionability remains confined to the limited subgroups of ERBB2 amplified, BRAF mutated and MSI-H patients. Optimizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f91192c02906f6f1a8603ae18f2cba4
https://doi.org/10.1200/jco.2021.39.15_suppl.3506
https://doi.org/10.1200/jco.2021.39.15_suppl.3506
Autor:
Giulia Orsi, M. Macchini, Evaristo Maiello, Luigi Cavanna, Fabrizio Artioli, Chiara Manai, N. Silvestris, Elisa Giommoni, Giovanni Gerardo Cardellino, M. Spada, V. Giugliano, M. Milella, Valter Torri, Francesca Bergamo, M. Di Marco, Michele Ghidini, Michele Reni, Luca Porcu, Giordano D. Beretta, M.M. Valente
Publikováno v:
Annals of Oncology. 31:S953
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fb772667b41b77773c311150946fb35
https://doi.org/10.1016/j.annonc.2020.08.2045
https://doi.org/10.1016/j.annonc.2020.08.2045
Autor:
Davide Melisi, Floriana Nappo, Sara Lonardi, Maria Antonietta Satolli, Silvia Noventa, Michele Milella, Guido Giordano, Clizia Zichi, Vanja Vaccaro, Annalisa Pappalardo, Elisa Giommoni, Chiara Manai, Mario Scartozzi, Michele Panebianco, Antonio Pellino, Camilla Zecchetto, Lorenzo Antonuzzo, Ferdinando De Vita, Marco Puzzoni, Valeria Merz
Publikováno v:
Journal of Clinical Oncology. 38:660-660
660 Background: In the NAPOLI I phase III trial, Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) showed better outcome compared to 5FU/LV in patients with metastatic Pancreatic Cancer (MPC) progressed to 1st- line gemcitab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbe7af3d83b66a076f1d81cf59132a56
https://doi.org/10.1200/jco.2020.38.4_suppl.660
https://doi.org/10.1200/jco.2020.38.4_suppl.660
Autor:
Francesca Bergamo, Cristina Granetto, Chiara Manai, Alfredo Falcone, S. Noventa, Daniele Santini, C. Cremolini, Daniele Rossini, Tiziana Latiano, Giovanni Randon, Andrea Antonuzzo, Chiara Carlomagno, Federica Marmorino, Andrea Sbrana, Roberto Moretto, Carlotta Antoniotti, Stefano Cordio, Monica Ronzoni, Federica Urbano, Michele Ghidini
Publikováno v:
Annals of Oncology. 30:iv114-iv115
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02c196abc5a8638461f863b1ace86444
https://doi.org/10.1093/annonc/mdz156.014
https://doi.org/10.1093/annonc/mdz156.014
Autor:
Vincenzo Dadduzio, Chiara Manai, Francesca Bergamo, Francesca Battaglin, Sara Lonardi, Vittorina Zagonel, Fotios Loupakis, Marta Schirripa
Publikováno v:
Expert opinion on biological therapy. 17(10)
Targeted agents alone or in combination with chemotherapy are current standard of treatment for metastatic colorectal cancer (mCRC). Panitumumab is a fully human monoclonal antibody which inhibits the epidermal growth factor receptor (EGFR). It is cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f7daaeae77dda541b7ca83968a74a5
https://pubmed.ncbi.nlm.nih.gov/28752777
https://pubmed.ncbi.nlm.nih.gov/28752777
Autor:
Antonella Brunello, Marta Schirripa, Giuseppina Tierno, Annunziata Lettiero, Vittorina Zagonel, Pasquale Fiduccia, Chiara Manai, G. Pusole, Francesca Bergamo, Letizia Procaccio, Sara Lonardi
Publikováno v:
Journal of Clinical Oncology. 37:11552-11552
11552 Background: About 50% of diagnoses of colorectal cancer (CRC) occur in patients (pts) older than 70 years. Though a comprehensive geriatric assessment (CGA) is recommended for proper management of older cancer pts, there is still no consensus o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cd25e204a43f1290564df364ff0c67a
https://doi.org/10.1200/jco.2019.37.15_suppl.11552
https://doi.org/10.1200/jco.2019.37.15_suppl.11552
Autor:
Alfredo Falcone, Francesca Bergamo, Chiara Manai, Chiara Carlomagno, Silvia Noventa, Federica Marmorino, Daniele Rossini, Cristina Granetto, Monica Ronzoni, Tiziana Latiano, Andrea Antonuzzo, Giovanni Randon, Chiara Cremolini, Federica Urbano, Andrea Sbrana, Carlotta Antoniotti, Michele Ghidini, Daniele Santini, Roberto Moretto, Stefano Cordio
Publikováno v:
Journal of Clinical Oncology. 37:11591-11591
11591 Background: FOLFOXIRI/bev is a valid option as first-line therapy for unresectable mCRC. TRIBE and TRIBE2 trials reported better activity and efficacy of the triplet/bev when compared with doublets/bev at the price of a higher incidence of chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72ee422a64515c7868bedff1867c0827
https://doi.org/10.1200/jco.2019.37.15_suppl.11591
https://doi.org/10.1200/jco.2019.37.15_suppl.11591